Sylvie R. B.
- Country
- France
- Department
- Service d’Immuno-Hématologie Clinique
Research Overview
- Evaluation of Safety, Pharmacokinetics, and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Patients Transitioning from Cabotegravir/Rilpivirine
- Evaluation of a Weekly Oral Islatravir/Lenacapavir Regimen Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Patients
Data & Insights
Has run more than one trial at 1 of 14 partner sites.
Specializations
HIV Treatment Innovation
The investigator specializes in advancing therapeutic strategies for HIV-1 infection, with particular focus on evaluating novel oral treatment regimens for virologically suppressed patients.
- Antiretroviral Therapy Optimization
- Treatment Switching Strategies
- Viral Suppression Management
Their research encompasses the evaluation of weekly oral medication regimens and transitioning between different therapeutic approaches.
Treatment Adherence Studies
The investigator examines the effectiveness of transitioning between injectable and oral HIV therapies, focusing on maintaining viral suppression during treatment changes.
- Patient Treatment Preferences
- Medication Administration Routes
- Treatment Continuation Strategies
Their work includes assessment of safety and efficacy in patients switching between different administration methods.
Clinical Management
The investigator focuses on long-term viral management strategies for HIV-positive individuals, particularly in maintaining therapeutic effectiveness during treatment transitions.
- Therapeutic Success Monitoring
- Alternative Treatment Options
- Patient-Centered Care Approaches
Their research emphasizes maintaining virologic suppression while exploring various treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.